CCG1423isaninhibitorofRhosignalingthatinhibitsserumresponsefactor(SRF);itdisplaysanti-metastatic,anti-diabetic,andanti-fibroticactivities.CCG1423bindsmyocardin-relatedtranscriptionfactorA(MRTF-A),preventingitsaccumulationandpotentiallyinhibitingtheepithelial-to-mesenchymaltransition(EMT).CCG1423alsoinhibitsinvasivenessofprostatecancercells.Inanimalmodelsofdiabetespathogenesis,thiscompoundimprovesglucoseuptakeandtolerance.
| CasNo. | 285986-88-1 |
|---|---|
| Purity | ≥98% |
| Formula | C18H13ClF6N2O3 |
| FormulaWt. | 454.75 |
| IUPACName | N-({1-[(4-Chlorophenyl)amino]-1-oxo-2-propanyl}oxy)-3,5-bis(trifluoromethyl)benzamide |
| StoreTemp | -20°C |
|---|---|
| ShipTemp | Ambient |
| InfoSheet | C0824InfoSheetPDF |
|---|
HayashiK,WatanabeB,NakagawaY,etal.RPELproteinsarethemoleculartargetsforCCG-1423,aninhibitorofRhosignaling.PLoSOne.2014Feb18;9(2):e89016.PMID:24558465.
BellJL,HaakAJ,WadeSM,etal.Optimizationofnovelnipecoticbis(amide)inhibitorsoftheRho/MKL1/SRFtranscriptionalpathwayaspotentialanti-metastasisagents.BioorgMedChemLett.2013Jul1;23(13):3826-32.PMID:23707258.
JinW,GoldfineAB,BoesT,etal.IncreasedSRFtranscriptionalactivityinhumanandmouseskeletalmuscleisasignatureofinsulinresistance.JClinInvest.2011Mar;121(3):918-29.PMID:21393865.
